AOD-9604 is the same fragment with an N-terminal tyrosine modification developed by Metabolic Pharmaceuticals to stabilize the molecule for clinical development

Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms

Most researchers assume that because peptides are endogenous signaling molecules and antidepressants are small-molecule drugs, they operate in separate pharmacological spaces
1,2,98 Pregnancy According to the EFSA, there is no evidence for teratogenicity or adverse effects on fertility or postnatal development with B12